Publikationen der AG Leifheit-Nestler

2020

Active vitamin D is cardioprotective in experimental uraemia but not in children with CKD stages 3-5.
Schön A*, Leifheit-Nestler M*, Deppe J, Fischer DC, Bayazit AK, Obrycki L, Canpolat N, Bulut IK, Azukaitis K, Yilmaz A, Mir S, Yalcinkaya F, Soylemezoglu O, Melk A, Stangl GI, Behnisch R, Shroff R, Bacchetta J, Querfeld U, Schaefer F, Haffner D; for the 4C Study consortium and the ESPN CKD-MBD working group. Nephrol Dial Transplant. 2020; in press
hier

Bone evaluation in paediatric chronic kidney disease: Clinical practice points from the European Society for Paediatric Nephrology chronic kidney disease-Mineral and bone disorder and dialysis working groups and the European Renal Osteodystrophy working group, an initiative of the CKD-MBD working group of the ERA-EDTA.
Sevcan A. Bakkaloglu SA*, Bacchetta J *, Lalayiannis AD, Leifheit-Nestler M, Stabouli S, Haarhaus ML, ReuszG, Groothoff J, Schmitt CP, Evenepoel P, Shroff R*, Haffner D*, on behalf of the European Society for Paediatric Nephrology (ESPN) Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) and Dialysis working groups and the European Renal Osteodystrophy (EUROD) workgroup, an Initiative of the CKD-MBD working group of the European Renal Association–European Dialysis and Transplantat Association (ERA-EDTA). Nephrol Dial Transplant. 2020; in press
hier

Bone and Mineral Metabolism in Children with Nephropathic Cystinosis Compared with other CKD Entities.
Ewert A, Leifheit-Nestler M, Hohenfellner K, Büscher A, Kemper MJ, Oh J, Billing H, Thumfart J, Stangl G, Bauer AC, Föller M, Feger M, Weber LT, Acham-Roschnitz B, Arbeiter K, Tönshoff B, Zivicnjak M, Haffner D. J Clin Endocriol Metab 2020; 105:dgaa267.
hier

CKD-MBD post kidney transplantation.
Haffner D and Leifheit-Nestler M. Pediatr Nephrol. 2020; in press
hier

Treatment of hyperphosphatemia: The dangers of aiming for normal PTH levels.
Haffner D and Leifheit-Nestler M. Pediatr Nephrol. 2020; 35:485-491.
hier

The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid.
Kranaster L, Hoyer C, Mindt S, Neumeier M, Müller N, Zill P, Schwarz MJ, Moll N, Lutz B, Bindila L, Zerr I, Schmitz M, Blennow K, Zetterberg H, Haffner D, Leifheit-Nestler M, Ozbalci C, Sartorius A. Eur Arch Psychiatry Clin Neurosci. 2020; 270:911-919.
hier

2019

FGF23 and phosphate – Cardiovascular toxins in CKD.
Vogt I, Haffner D and Leifheit-Nestler M. Toxins (Basel). 2019; 11:647.
hier

FGF23-mediated activation of RAAS promotes cardiac hypertrophy and fibrosis.
Böckmann I, Lischka J, Richter B, Deppe J, Rahn A, Fischer DC, Heineke J, Haffner D, Leifheit-Nestler M. Int J Mol Sci. 2019; 20:4634.
hier

Peripheral levels of anti-aging hormone Klotho in patients with depression.
Sartorius A, Gilles M, Pfeifer AM, Deuschle M, Hoyer C, Haffner D, Leifheit-Nestler M, Kranaster L. J Neural Transm (Vienna). 2019; 126:771-776.
hier

Biomarker of Antidepressant Efficacy of Electroconvulsive Theraphy: An Exploratory Cerebrospinal Fluid Study.
Kranaster L, Hoyer C, Aksay SS, Bumb JM, Müller N, Zill P, Schwarz MJ, Moll N, Lutz B, Bindila L, Zerr I, Schmitz M, Blennow K, Zetterberg H, Haffner D, Leifheit-Nestler M, Ozbalci C, Janke C, Thiel M, Sartorius A. Neuropsychobiology. 2019; 77:13-22.
hier

2018

Impact of altered mineral metabolism on pathological cardiac remodeling in elevated fibroblast growth factor 23.
Leifheit-Nestler M, Richter B, Basaran M, Nespor J, Vogt I, Alesutan I, Voelkl J, Lang F, Heineke J, Kricks, Haffner D. Front Endocrinol (Lausanne). 2018; 9:333.
hier

Paracrine effects of FGF23 on the heart.
Leifheit-Nestler M and Haffner D. Front Endocrinol (Lausanne). 2018; 9:278.
hier

Impaired microcirculation in children after kidney transplantation: Everolimus versus myophenolate based immunosuppression regimen.
Ruben S, Kreuzer M, Büscher A, Büscher R, Thumfart J, Querfeld U, Staude H, Ahlenstiel-Grunow T, Melk A, Fischer DC, Leifheit-Nestler M, Pape L, Haffner D. Kidney Blood Press Res. 2018; 43:793-806.
hier

Effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism in children with CKD.
Lerch C, Shroff R, Wan M, Rees L, Aitkenhead H, Bulut IP, Thurn D, Bayazit AK Nimierska A, Canpolat N, Duzova A, Azukaitis K, Yimaz E, Yalcinkaya F, Harambat J, Kiyak A, Alpay H, Anarat A, Habbig S, Wygoda S, Zaloszyk A, Soylemezoglu O, Caliskan S, Baskin E, Candan C, Rosales A, Melk A, Querfeld U, Leifheit-Nestler M, Sander A, Schaefer F, Haffner D; for the 4C Study consortium and the ESPN CKD-MBD working group. Nephrol Dial Transplant. 2018; 33:2208-2217.
hier

Fibroblast growth factor 23 is induced by activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts.
Leifheit-Nestler M, Kirchhoff F, Nespor J, Richter B, Soetje B, Klintschar M, Heineke J, Haffner D. Nephrol Dial Transplant. 2018; 33:1722-1734.
hier

Electroconvulsive therapy enhances the anti-ageing hormone Klotho in the cerebrospinal fluid of patients with major depression.
Hoyer C, Sartorius A, Aksay SS, Bumb JM, Janke C, Thiel M, Haffner D, Leifheit-Nestler M*, Kranaster L*. Eur Neuropsychopharmacol. 2018; 28:428-435.
*These authors contributed equally to this work
hier

2017

Comparision of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mous, a murine homolog of X-linked hyperphosphatemia.
Leifheit-Nestler M, Kucka J, Yoshizawa E, Behets G, D´Haese P, Bergen C, Meier M, Fischer DC, Haffner D. Bone. 2017; 103:224-232.
hier

Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.
Leifheit-Nestler M, Grabner A, Hermann L, Richter B, Schmitz K, Fischer DC, Yanucil C, Faul C, Haffner D. Nephrol Dial Transplant. 2017; 32:1493-1503.
hier

Endothelial dysfunction during long-term follow-up in children with STEC hemolytic-uremic syndrome.
Kreuzer M, Sollmann L, Ruben S, Leifheit-Nestler M, Fischer DC, Pape L, Haffner D. Pediatr Nephrol. 2017; 32:1005-1011.
hier

Extrarenal effects of FGF23.
Haffner D and Leifheit-Nestler M. Pediatr Nephrol. 2017; 32:753-765.
hier

Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells.
Richter B, Haller J, Haffner D, Leifheit-Nestler M. Pfluger Arch. 2016; 468:1621-1635.
hier

Klotho and Fibroblast Growth Factor 23 in Cerebrospinal Fluid in Children.
Kunert SK, Hartmann H, Haffner D, Leifheit-Nestler M. J Bone Mineral Metab. 2017; 35:215-226.
hier

2016

Fibroblast growth factor 23 signaling in hippocampal cells: Impact on neuronal morphology and synaptic density.
Hensel N, Schön A, Konen T, Lübben V, Förthmann B, Baron O, Grothe C, Leifheit-Nestler M*, Claus P*, Haffner D*. J Neurochem. 2016; 137:756-769.
*These authors contributed equally to this work
hier

Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
Leifheit-Nestler M, große Siemer R, Flasbart K, Richter B, Kirchhoff K, Ziegler WH, Klintschar M, Becker JU, ErbersdoblerA, Aufricht C, Seeman T, Fischer DC, Faul C, Haffner D. Nephrol Dial Transplant. 2016; 31:1088-1099.
hier

2015

Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.
Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstädt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C. Cell Metab. 2015; 22:1020-1032.
hier

Zurück zur Arbeitsgruppe